Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Glaxosmithkline IPF study -- This was GSK's P

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155610
(Total Views: 613)
Posted On: 02/02/2025 8:30:54 PM
Posted By: My69z
Glaxosmithkline IPF study --

This was GSK's Phase 1:

GSK3915393 is a small molecule currently being investigated as a potential treatment for Idiopathic Pulmonary Fibrosis (IPF), and according to available information, a Phase 1 clinical trial has already been completed in healthy volunteers to assess its safety and tolerability, primarily focusing on drug interactions with grapefruit juice and the antifungal medication itraconazole.

Key points about GSK3915393 in Phase 1:
Target mechanism:

This drug works by targeting transglutaminase-2 (TG2).

Study population: Healthy volunteers were used in the Phase 1 trial.

Primary focus:
Evaluating the safety profile of the drug, including potential interactions with other medications.

Current status: Phase 1 trials have been completed, and further studies are likely needed to assess its efficacy in treating IPF patients.
__
Only in Phase 2:

A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) was last updated on Jan 20, 2025.

ctv.veeva.com/study/a-study...

Through Max post our CCL4 results:
*GSK buys our PF/IPF rights?
Fund to market & royalties.

*Gates Vascular site for trials.
IPF kills 1m a year.

Other than healthy volunteers were used in GSK trial & Leronlimab is the non-toxic of unmet needs: actual CCL4 results coming.

& LL will/would have a (+) combo effect ?

What are the neurological side effects of itraconazole?

Peripheral neuropathy, paresthesia, hypoesthesia, headache, dizziness, tinnitus, transient/permanent hearing loss, dysgeusia, and tremor have also been reported during post-marketing experience. Sep 6, 2024

& I just babbled Friday about LL not having shown any post-trial FDA issues.

Wow.

Think Max has GSK's IPF ear ?
I do.


(7)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us